Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples

Abraham, 2015, GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX, 1–2, 19, 10.1016/j.softx.2015.06.001 Asselta, 2003, The discovery of Mary's mutation, J. Thromb. Haemost., 1, 397, 10.1046/j.1538-7836.2003.00151.x Becker, 2010, Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics, Thromb. Haemost., 103, 586, 10.1160/TH09-10-0716 Bertina, 1994, Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, 369, 64, 10.1038/369064a0 Bock, 1992, Selection of single-stranded DNA molecules that bind and inhibit human thrombin, Nature, 355, 564, 10.1038/355564a0 Bolliger, 2010, Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution, Anesthesiology, 113, 1205, 10.1097/ALN.0b013e3181f22b5a Bompiani, 2014, Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation, Chem. Biol., 21, 935, 10.1016/j.chembiol.2014.05.016 Bompiani, 2012, Antidote control of aptamer therapeutics: the road to a safer class of drug agents, Curr. Pharm. Biotechnol., 13, 1924, 10.2174/138920112802273137 Boniecki, 2016, SimRNA: a coarse-grained method for RNA folding simulations and 3D structure prediction, Nucleic Acids Res., 44, e63, 10.1093/nar/gkv1479 Bradford, 2010, Regulated cleavage of prothrombin by prothrombinase: repositioning a cleavage site reveals the unique kinetic behavior of the action of prothrombinase on its compound substrate, J. Biol. Chem., 285, 328, 10.1074/jbc.M109.070334 Bradford, 2013, Membrane binding by prothrombin mediates its constrained presentation to prothrombinase for cleavage, J. Biol. Chem., 288, 27789, 10.1074/jbc.M113.502005 Buddai, 2010, An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase, J. Biol. Chem., 285, 5212, 10.1074/jbc.M109.049833 Bunce, 2013, Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides, J. Biol. Chem., 288, 30151, 10.1074/jbc.M113.506840 Burrell, 2017, A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release, J. Thromb. Haemost., 15, 1807, 10.1111/jth.13760 Carpenter, 2019, Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation, Ther. Adv. Drug Saf., 10, 10.1177/2042098619888133 Chabata, 2018, Emerging applications of aptamers for anticoagulation and hemostasis, Curr. Opin. Hematol., 25, 382, 10.1097/MOH.0000000000000452 Dahlback, 1993, Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C, Proc. Natl. Acad. Sci. U S A, 90, 1004, 10.1073/pnas.90.3.1004 Dunn, 2017, Analysis of aptamer discovery and technology, Nat. Rev. Chem., 1, 0076, 10.1038/s41570-017-0076 Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 Frederiksen, 2000, Cardiopulmonary bypass in humans: bypassing unfractionated heparin, Ann. Thorac. Surg., 70, 1434, 10.1016/S0003-4975(00)01511-3 Gelinas, 2016, Embracing proteins: structural themes in aptamer-protein complexes, Curr. Opin. Struct. Biol., 36, 122, 10.1016/j.sbi.2016.01.009 Gregg, 1997, Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations, Am. J. Med. Genet., 73, 334, 10.1002/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J Gunaratne, 2018, Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass, Nat. Biotechnol., 36, 606, 10.1038/nbt.4153 Harter, 2015, Anticoagulation drug therapy: a review, West J. Emerg. Med., 16, 11, 10.5811/westjem.2014.12.22933 Horton, 2013, Activated clotting time (ACT), Methods Mol. Biol., 992, 155, 10.1007/978-1-62703-339-8_12 Ivanciu, 2014, New insights into the spatiotemporal localization of prothrombinase in vivo, Blood, 124, 1705, 10.1182/blood-2014-03-565010 Izumi, 2001, Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding, Thromb. Haemost., 85, 1048, 10.1055/s-0037-1615962 Kozakov, 2017, The ClusPro web server for protein-protein docking, Nat. Protoc., 12, 255, 10.1038/nprot.2016.169 Krishnaswamy, 1987, Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism, J. Biol. Chem., 262, 3291, 10.1016/S0021-9258(18)61503-0 Layzer, 2007, Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection, Oligonucleotides, 17, 1, 10.1089/oli.2006.0059 Lincoff, 2016, Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial, Lancet, 387, 349, 10.1016/S0140-6736(15)00515-2 Long, 2008, Crystal structure of an RNA aptamer bound to thrombin, RNA, 14, 2504, 10.1261/rna.1239308 Macedo-Ribeiro, 1999, Crystal structures of the membrane-binding C2 domain of human coagulation factor V, Nature, 402, 434, 10.1038/46594 Mann, 2003, Factor V: a combination of Dr Jekyll and Mr Hyde, Blood, 101, 20, 10.1182/blood-2002-01-0290 Moores, 2020, Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report, Chest, 158, 1143, 10.1016/j.chest.2020.05.559 Namendys-Silva, 2020, ECMO for ARDS due to COVID-19, Heart Lung, 49, 348, 10.1016/j.hrtlng.2020.03.012 Oney, 2009, Development of universal antidotes to control aptamer activity, Nat. Med., 15, 1224, 10.1038/nm.1990 Oney, 2007, Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers, Oligonucleotides, 17, 265, 10.1089/oli.2007.0089 Orban, 2005, Completed three-dimensional model of human coagulation factor va. Molecular dynamics simulations and structural analyses, Biochemistry, 44, 13082, 10.1021/bi050891t Orcutt, 2004, Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin, J. Biol. Chem., 279, 54927, 10.1074/jbc.M410866200 Pabinger, 2015, Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS), J. Thromb. Haemost., 13, 17, 10.1111/jth.12778 Pellequer, 2000, Three-dimensional model of coagulation factor Va bound to activated protein C, Thromb. Haemost., 84, 849, 10.1055/s-0037-1614127 Povsic, 2013, A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial, Eur. Heart J., 34, 2481, 10.1093/eurheartj/ehs232 Rosing, 1980, The role of phospholipids and factor Va in the prothrombinase complex, J. Biol. Chem., 255, 274, 10.1016/S0021-9258(19)86294-4 Rusconi, 2004, Antidote-mediated control of an anticoagulant aptamer in vivo, Nat. Biotechnol., 22, 1423, 10.1038/nbt1023 Rusconi, 2002, RNA aptamers as reversible antagonists of coagulation factor IXa, Nature, 419, 90, 10.1038/nature00963 Rusconi, 2000, Blocking the initiation of coagulation by RNA aptamers to factor VIIa, Thromb. Haemost., 84, 841, 10.1055/s-0037-1614126 Schmidt, 2020, Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study, Lancet Respir. Med., 8, 1121, 10.1016/S2213-2600(20)30328-3 Singhania, 2020, Current overview on hypercoagulability in COVID-19, Am. J. Cardiovasc. Drugs, 20, 393, 10.1007/s40256-020-00431-z Soule, 2016, Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant, Nucleic Acid Ther., 26, 1, 10.1089/nat.2015.0565 Tasset, 1997, Oligonucleotide inhibitors of human thrombin that bind distinct epitopes, J. Mol. Biol., 272, 688, 10.1006/jmbi.1997.1275 Toso, 2004, Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized, J. Biol. Chem., 279, 21643, 10.1074/jbc.M402107200 Tracy, 1982, Radioimmunoassay of factor V in human plasma and platelets, Blood, 60, 59, 10.1182/blood.V60.1.59.59 Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121 White, 2001, Generation of species cross-reactive aptamers using "toggle" SELEX, Mol. Ther., 4, 567, 10.1006/mthe.2001.0495 Woodruff, 2013, Inhibiting the activation of the intrinsic pathway with a FXII-targeting RNA aptamer, J. Thromb. Haemost., 11, 959, 10.1111/jth.12302 Woodruff, 2017, Generation and characterization of aptamers targeting factor XIa, Thromb. Res., 156, 134, 10.1016/j.thromres.2017.06.015 Woodruff, 2011, The many faces of the contact pathway and their role in thrombosis, J. Thromb. Thrombolysis, 32, 9, 10.1007/s11239-011-0578-5 Woodruff, 2015, Modulation of the coagulation cascade using aptamers, Arterioscler. Thromb. Vasc. Biol., 35, 2083, 10.1161/ATVBAHA.115.300131 Yavari, 2008, Anticoagulant therapy during cardiopulmonary bypass, J. Thromb. Thrombolysis, 26, 218, 10.1007/s11239-008-0280-4 Zuker, 2003, Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Res., 31, 3406, 10.1093/nar/gkg595